Psoriasis treatment: traditional therapy

Lebwohl, Mark; Ting, Patricia T.; Koo, John

doi:10.1136/ard.2004.030791

Cited by 93 publications

(77 citation statements)

References 34 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Criteria to be fulfilled in obtaining the best-fitted model were high F-value, low P-value (,0.05), insignificant lack of fit, high R 2 , low standard deviation, a randomly scattered plot of residuals, and whether it was able to predict the validation set well. 31 Following are the equations that expressed the quadratic model for the prediction of particle size ( (14) where X 1 , X 2 , X 3 , and X 4 represent the independent variables of oil content, surfactant content, xanthan gum content and water content in w/w (%), respectively. Graphs of predicted …”

Section: Results and Discussion Solubility Of Cyclosporine Analysismentioning

confidence: 99%

Enhancement of physicochemical properties of nanocolloidal carrier loaded with cyclosporine for topical treatment of psoriasis: in vitro diffusion and in vivo hydrating action

Sh¹,

Basri²,

HR³

et al. 2017

IJN

View full text Add to dashboard Cite

Section: Results and Discussion Solubility Of Cyclosporine Analysismentioning

confidence: 99%

Enhancement of physicochemical properties of nanocolloidal carrier loaded with cyclosporine for topical treatment of psoriasis: in vitro diffusion and in vivo hydrating action

Sh¹,

Basri²,

HR³

et al. 2017

IJN

View full text Add to dashboard Cite

“…Although many patients with mild‐to‐moderate psoriasis are treated with topical therapy alone,6, 7, 8 adherence remains a significant issue as the daily treatment regimen can be cumbersome and time consuming 9. Studies have shown that the type of topical vehicle used can impact on adherence;10, 11 patients prefer a vehicle that is simple and fast to apply, quickly absorbed and non‐greasy 12…”

Section: Introductionmentioning

confidence: 99%

Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO‐ABLE study

Paul

Gold

Cambazard

et al. 2016

Acad Dermatol Venereol

104

167

View full text Add to dashboard Cite

BackgroundFixed combination calcipotriol 50 μg/g (Cal) plus betamethasone 0.5 mg/g (BD) foam has been developed as a new treatment option for patients with psoriasis.MethodsThe randomized, parallel‐group, investigator‐blinded Phase III, 12‐week PSO‐ABLE study compared the efficacy and safety of Cal/BD foam with Cal/BD gel. Patients aged ≥18 years with mild‐to‐severe psoriasis were randomized 4:4:1:1 to once‐daily Cal/BD foam, Cal/BD gel, foam vehicle or gel vehicle (NCT02132936). The primary efficacy endpoint was the proportion of patients who were clear/almost clear with a ≥ 2 grade improvement according to the physician's global assessment of disease severity (i.e. treatment success) at week 4 for Cal/BD foam vs. week 8 for Cal/BD gel. Secondary efficacy endpoints included: proportion of patients achieving at least a 75% reduction in modified psoriasis area and severity index (mPASI75), and time to treatment success (TTTS). Safety was monitored throughout.ResultsA total of 463 patients were randomized: Cal/BD foam (n = 185), Cal/BD gel (n = 188), foam vehicle (n = 47), gel vehicle (n = 43); overall completion rate was 90%. Cal/BD foam achieved higher treatment success rates (38% vs. 22%; P < 0.001) and mPASI75 (52% vs. 35%; P < 0.001) by week 4 than Cal/BD gel by week 8. Median TTTS with Cal/BD foam was 6 weeks; this could not be determined for Cal/BD gel as 50% treatment success was not achieved (P < 0.001). Adverse drug reactions were reported in 14 (7.6%) Cal/BD aerosol foam patients and 7 (3.7%) Cal/BD gel patients; all were single events except for itch with Cal/BD aerosol foam (n = 5; 2.7%) and worsening psoriasis with Cal/BD gel (n = 3; 1.6%).ConclusionCal/BD aerosol foam showed significantly greater efficacy after 4 weeks, than 8 weeks of treatment with Cal/BD gel, with similar tolerability.

show abstract

“…In psoriasis, mast cells, key cellular drivers of cytokine expression and perpetuation of lesions, are found activated and in greater number in the papillary dermis [12]. Antioxidant properties of vitamin A and its derivatives have also been implicated in its efficacy on psoriatic plaques [13,14].…”

Section: Vitamin Amentioning

confidence: 99%

Psoriasis and Fat-soluble Vitamins: A Review

Usedom¹,

Neidig²,

Allen³

2017

J Clin Exp Dermatol Res

View full text Add to dashboard Cite

Fat-soluble vitamins exhibit numerous routes of immune modulation and specifically alter a variety of pathways in psoriasis pathology. Psoriasis, a chronic immune-mediated disease, often requires a combination of topical, oral, and occasionally, subcutaneous or intravenous therapies making disease management complex. With the complexity of treatment, patient adherence is reduced. Vitamin supplementation as an adjunctive treatment would minimize potential adverse effects from systemic medication, increase patient adherence and decrease overall cost. While vitamin A and D are effective topically, oral supplementation is not currently a mainstay of therapy although data exists to support such supplementation. Data on vitamin E and K implicate the significant role each has in the alteration of the inflammatory cascade responsible for psoriasis. Research showing fat-soluble vitamin deficiency in psoriasis exists and presents greater evidence for oral vitamin treatment in addition to first-line therapies. This review presents the mechanism of action in psoriasis of each fat-soluble vitamin and the data on the efficacy of oral fat-soluble vitamin supplementation in psoriasis and systemic inflammation. We also present fat-soluble vitamin deficiency data shown in psoriasis patients. With the evidence of their targeted mechanism of action, efficacy data with oral supplementation, and evidence of deficiency in patients, oral fat-soluble vitamins should be considered as an adjunct to therapy in psoriasis patients.

show abstract

Psoriasis treatment: traditional therapy

Cited by 93 publications

References 34 publications

Enhancement of physicochemical properties of nanocolloidal carrier loaded with cyclosporine for topical treatment of psoriasis: in vitro diffusion and in vivo hydrating action

Enhancement of physicochemical properties of nanocolloidal carrier loaded with cyclosporine for topical treatment of psoriasis: in vitro diffusion and in vivo hydrating action

Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO‐ABLE study

Psoriasis and Fat-soluble Vitamins: A Review

Contact Info

Product

Resources

About